Compare Stocks: SXTC, LIAN, REVB, and GRI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GRI GRI Bio	$1.90 -2.1%	$1.76	$1.36 ▼ $64.12	$4.24M	-1.24	566,724 shs	131,734 shs
LIAN LianBio	$0.05 +37.7%	$0.06	$0.27 ▼ $4.99	$5.61M	0.23	1.04 million shs	674 shs
REVB Revelation Biosciences	$0.99 -0.7%	$1.06	$0.88 ▼ $8.04	$3.98M	-0.14	40,349 shs	3,617 shs
SXTC China SXT Pharmaceuticals	$2.56 +32.6%	$54.78	$1.78 ▼ $83,758.80	$920K	1.85	1.74 million shs	14.08 million shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GRI GRI Bio	+7.78%	-15.28%	-11.82%	-13.78%	-95.56%
LIAN LianBio	0.00%	-5.75%	-2.33%	-65.91%	-29.93%
REVB Revelation Biosciences	-1.49%	-1.49%	-10.36%	-0.13%	-89.93%
SXTC China SXT Pharmaceuticals	-9.81%	-12.27%	-45.01%	-99.06%	-99.99%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GRI GRI Bio	$1.90 -2.1%	$1.76	$1.36 ▼ $64.12	$4.24M	-1.24	566,724 shs	131,734 shs
LIAN LianBio	$0.05 +37.7%	$0.06	$0.27 ▼ $4.99	$5.61M	0.23	1.04 million shs	674 shs
REVB Revelation Biosciences	$0.99 -0.7%	$1.06	$0.88 ▼ $8.04	$3.98M	-0.14	40,349 shs	3,617 shs
SXTC China SXT Pharmaceuticals	$2.56 +32.6%	$54.78	$1.78 ▼ $83,758.80	$920K	1.85	1.74 million shs	14.08 million shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GRI GRI Bio	+7.78%	-15.28%	-11.82%	-13.78%	-95.56%
LIAN LianBio	0.00%	-5.75%	-2.33%	-65.91%	-29.93%
REVB Revelation Biosciences	-1.49%	-1.49%	-10.36%	-0.13%	-89.93%
SXTC China SXT Pharmaceuticals	-9.81%	-12.27%	-45.01%	-99.06%	-99.99%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GRI GRI Bio	2.33	Hold	$21.00	1,005.26% Upside
LIAN LianBio	0.00	N/A	N/A	N/A
REVB Revelation Biosciences	1.00	Sell	N/A	N/A
SXTC China SXT Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest SXTC, LIAN, REVB, and GRI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	GRI GRI Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/31/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/25/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/11/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/11/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/28/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/28/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/17/2026	GRI GRI Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/10/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/9/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/25/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)

(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GRI GRI Bio	N/A	N/A	N/A	N/A	$4.16 per share	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	$2.71 per share	N/A
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	$1.28 per share	N/A
SXTC China SXT Pharmaceuticals	$1.14M	1.08	N/A	N/A	$2,468.59 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GRI GRI Bio	-$11.96M	-$38.37	N/A	N/A	N/A	N/A	-134.03%	-106.83%	11/13/2026 (Estimated)
LIAN LianBio	-$110.29M	-$0.81	N/A	N/A	N/A	N/A	-33.17%	-30.19%	N/A
REVB Revelation Biosciences	-$8.91M	-$12.31	N/A	N/A	N/A	N/A	-100.19%	-82.72%	11/5/2026 (Estimated)
SXTC China SXT Pharmaceuticals	-$6.20M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest SXTC, LIAN, REVB, and GRI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	GRI GRI Bio	-$1.19	-$0.91	+$0.28	-$0.91	N/A	N/A
8/6/2026	Q2 2026	REVB Revelation Biosciences	-$0.8750	-$0.87	+$0.0050	-$0.87	N/A	N/A
7/1/2026	Q4 2026	SXTC China SXT Pharmaceuticals	N/A	$6.84	N/A	$6.8350	N/A	$0.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GRI GRI Bio	N/A	N/A	N/A	N/A	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	N/A
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GRI GRI Bio	N/A	10.30	10.30
LIAN LianBio	N/A	10.06	10.06
REVB Revelation Biosciences	N/A	6.22	6.22
SXTC China SXT Pharmaceuticals	0.02	7.94	7.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GRI GRI Bio	33.95%
LIAN LianBio	74.85%
REVB Revelation Biosciences	12.80%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
GRI GRI Bio	8.73%
LIAN LianBio	7.59%
REVB Revelation Biosciences	4.80%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GRI GRI Bio	1	2.19 million	2.00 million	Not Optionable
LIAN LianBio	110	108.06 million	99.86 million	Not Optionable
REVB Revelation Biosciences	10	3.98 million	3.79 million	Not Optionable
SXTC China SXT Pharmaceuticals	90	480,000	459,000	Not Optionable

SXTC, LIAN, REVB, and GRI Headlines

Recent News About These Companies

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

August 5, 2026 | globenewswire.com

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

July 24, 2026 | globenewswire.com

China SXT Pharmaceuticals Raises $9 Million in Registered Direct Offering

July 24, 2026 | tipranks.com

China SXT Pharmaceuticals Enters $9 Million Registered Direct Offering of Units to Institutional Investors

July 23, 2026 | quiverquant.comQ

China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering

July 23, 2026 | globenewswire.com

China SXT Pharmaceuticals Inc. Cl A

July 14, 2026 | barrons.com

China SXT Pharmaceuticals shares surge over 25% after hours: Here's why

June 2, 2026 | msn.com

China SXT Pharmaceuticals Launches $100 Million ATM Equity Program with Univest Securities

June 1, 2026 | tipranks.com

China SXT Pharmaceuticals Raises $3.5 Million in Offshore Private Placement

May 11, 2026 | theglobeandmail.com

China Sxt Pharmaceuticals, Inc. Class A

April 7, 2026 | edition.cnn.com

China SXT Pharmaceuticals, Inc. Announces Share Re-classification

March 23, 2026 | globenewswire.com

This nano-cap pharma stock crashed 30% today – what triggered the sell-off?

January 30, 2026 | msn.com

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

January 30, 2026 | globenewswire.com

CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN

January 15, 2026 | finance.yahoo.com

Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)

January 13, 2026 | globenewswire.com

Why China SXT Pharmaceuticals, Inc.’s (SXTC) Stock Is Down 8.81%

January 11, 2026 | aaii.comA

China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering

January 9, 2026 | globenewswire.com

CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND ...

January 8, 2026 | markets.businessinsider.com

Why China SXT Pharmaceuticals, Inc.’s (SXTC) Stock Is Up 6.88%

January 3, 2026 | aaii.comA

China SXT Pharmaceuticals Full Year 2025 Earnings: US$2.32 loss per share (vs US$28.58 loss in FY 2024)

August 2, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SXTC, LIAN, REVB, and GRI Company Descriptions

GRI Bio NASDAQ:GRI

$1.90 -0.04 (-2.06%)

Closing price 04:00 PM Eastern

Extended Trading

$1.86 -0.04 (-2.37%)

As of 07:42 PM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

LianBio NASDAQ:LIAN

$0.05 +0.01 (+37.70%)

As of 09/10/2026

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Revelation Biosciences NASDAQ:REVB

$0.99 -0.01 (-0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$0.99 +0.00 (+0.06%)

As of 07:30 PM Eastern

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

China SXT Pharmaceuticals NASDAQ:SXTC

$2.56 +0.63 (+32.64%)

Closing price 04:00 PM Eastern

Extended Trading

$2.58 +0.02 (+0.98%)

As of 07:59 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTC, LIAN, REVB, and GRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTC, LIAN, REVB, and GRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTC, LIAN, REVB, and GRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SXTC, LIAN, REVB, and GRI Company Descriptions

GRI Bio NASDAQ:GRI

LianBio NASDAQ:LIAN

Revelation Biosciences NASDAQ:REVB

China SXT Pharmaceuticals NASDAQ:SXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTC, LIAN, REVB, and GRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTC, LIAN, REVB, and GRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTC, LIAN, REVB, and GRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SXTC, LIAN, REVB, and GRI Company Descriptions

GRI Bio NASDAQ:GRI

LianBio NASDAQ:LIAN

Revelation Biosciences NASDAQ:REVB

China SXT Pharmaceuticals NASDAQ:SXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools